Inflammatory Bowel Disease Treatment Market Report 2026

Inflammatory Bowel Disease Treatment Market Overview

• Inflammatory Bowel Disease Treatment market size has reached to $27.19 billion in 2025 • Expected to grow to $43.36 billion in 2030 at a compound annual growth rate (CAGR) of 9.8% • Growth Driver: The Surge In Inflammatory Bowel Diseases Spurs Growth In Treatment Market • Market Trend: Innovative Treatments For Moderate To Severe Active ulcerative colitis Enhance Market Growth • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Inflammatory Bowel Disease Treatment Market?

Inflammatory bowel disease treatment refers to anti-inflammatory medications that are commonly used to treat mild to moderate ulcerative colitis. Aminosalicylates such as mesalamine (Delzicol, Rowasa, and other brands), balsalazide (Colazal), and olsalazine are anti-inflammatories (Dipentum). The main drug class of inflammatory bowel disease treatment include aminosalicylates, corticosteroids, TNF inhibitors, IL inhibitors, anti-integrin, JAK inhibitors, and others. Aminosalicylates refer to a class of medications used to treat and prevent ulcerative colitis flare-ups and Crohn's disease. The functioning of aminosalicylates is based on inhibiting the production of cyclo-oxygenase and prostaglandin, thromboxane synthetase, platelet-activating factor synthetase, and interleukin-1 by macrophages. Both orally and injectable administered inflammatory bowel disease treatment are used in the treatment of Crohn’s disease and ulcerative colitis. These drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Inflammatory Bowel Disease Treatment Market Growth Forecast?

The inflammatory bowel disease treatment market size is expected to see strong growth in the next few years. It will grow to $43.36 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to increasing investment in precision medicine, development of novel anti-inflammatory therapies, integration of digital health platforms for patient monitoring, growth in biologics and biosimilars adoption, expansion of ibd treatment access in emerging markets. Major trends in the forecast period include personalized ibd therapy development, increasing use of biologics in treatment, minimally invasive drug delivery systems, rising focus on patient adherence programs, growth of specialty pharmacies for ibd.

Global Inflammatory Bowel Disease Treatment Market Segmentation

1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes 2) By Type: Crohn's Disease, Ulcerative Colitis 3) By Route Of Administration: Oral, Injectable 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments: 1) By Aminosalicylates: Mesalamine, Sulfasalazine, Balsalazide 2) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone 3) By TNF Inhibitors: Infliximab, Adalimumab, Certolizumab pegol 4) By IL Inhibitors: Ustekinumab, Guselkumab 5) By Anti-Integrin: Vedolizumab, Natalizumab 6) By JAK Inhibitors: Tofacitinib, Filgotinib 7) By Other Drug Classes: Antibiotics, Immunosuppressants, Other Novel Therapies

What Is The Driver Of The Inflammatory Bowel Disease Treatment Market?

The rising prevalence of Crohn’s disease and ulcerative colitis is significantly driving the inflammatory bowel disease treatment market. Crohn’s disease and ulcerative colitis are types of inflammatory bowel diseases (IBD) that cause inflammation and ulcers (sores) in the digestive tract. The rising cases of Crohn’s disease and ulcerative colitis are expected to boost demand for inflammatory bowel disease treatments, as they are widely used to reduce bowel inflammation and reduce and prevent medical complications. For instance, in November 2024, according to the Crohn's & Colitis Foundation, a US-based Non-profit organization, approximately 100,429 children and adolescents in the United States under 20 years old are affected by IBD, encompassing both Crohn’s disease and ulcerative colitis. Among this pediatric population, Crohn’s disease is more common, with a prevalence of 71 per 100,000, compared to 44 per 100,000 for ulcerative colitis. Hence, the rising prevalence of Crohn's disease and ulcerative colitis is expected to drive the inflammatory bowel disease treatment industry growth.

Key Players In The Global Inflammatory Bowel Disease Treatment Market

Major companies operating in the inflammatory bowel disease treatment market are AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals Inc., Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc., Advanced Gastroenterology and Surgery Associates P.A., Atlanta Gastroenterology Associates LLC, Digestive Disease Associates of Rockland P.C., Gastrointestinal Specialists Inc., Illinois Gastroenterology Group LLC, Massachusetts General Hospital, Mayo Clinic, Mount Sinai Health System Inc., The Oregon Clinic – Gastroenterology West P.C.

Global Inflammatory Bowel Disease Treatment Market Trends and Insights

Major companies operating in the inflammatory bowel disease treatment market are developing innovative products, such as treatments for moderate to severe active ulcerative colitis, to meet larger customer bases, more sales, and increase revenue. Treatments for moderate to severe active ulcerative colitis typically include medications and sometimes surgical interventions. For instance, in October 2023, Eli Lilly and Company, a US-based pharmaceutical company, announced the U. S. Food and Drug Administration (FDA) approval for Omvoh (mirikizumab-mrkz), available in both infusion (300 mg/15 mL) and injection (100 mg/mL) forms, is the inaugural and sole interleukin-23p19 (IL-23p19) antagonist designed to treat adults with moderately to severely active ulcerative colitis (UC). Omvoh is specifically tailored to focus on the p19 subunit of IL-23, effectively blocking the IL-23 pathway, which is responsible for the inflammation that significantly contributes to the development of UC. The Omvoh treatment regimen begins with three 300-mg IV infusions, administered once a week every four weeks, and then shifts to a maintenance phase involving two 100-mg subcutaneous self-injections every four weeks.

What Are Latest Mergers And Acquisitions In The Inflammatory Bowel Disease Treatment Market?

In November 2023, Teva Pharmaceuticals, a US-based provider of inflammatory bowel disease treatment, collaborated with Sanofi to advance innovative therapies. Through this partnership, Teva aims to accelerate the development of TEV ‘574, its investigational therapy for inflammatory bowel disease, by leveraging Sanofi’s global clinical and commercial expertise. The collaboration is expected to support the progression of TEV ‘574 through clinical trials and expand its worldwide market potential. Sanofi is a France-based pharmaceutical industry company.

Regional Insights

North America was the largest region in the inflammatory bowel disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Inflammatory Bowel Disease Treatment Market?

The inflammatory bowel disease treatment market includes revenues earned by entities by reducing the inflammation that triggers the signs and symptoms. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Inflammatory Bowel Disease Treatment Market Report 2026?

The inflammatory bowel disease treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the inflammatory bowel disease treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.